| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.06 | 0.2 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.061 | 0.2 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.067 | 0.2 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.2 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.062 | 0.2 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | -0.067 | 0.2 |